8-K: Trinseo Faces NYSE Delisting Threat Over Market Cap, Share Price

Trinseo PLC received a notice from the NYSE for non-compliance with minimum market capitalization and share price listing standards, initiating cure periods.

Summary

• Trinseo PLC received a notice from the New York Stock Exchange (NYSE) on December 12, 2025, indicating non-compliance with two continued listing standards.
• The company failed the Minimum Market Capitalization Standard (Section 802.01B) because its average global market capitalization over a 30-trading-day period was approximately $35.6 million, which is below the NYSE's $50 million minimum, and its stockholders' equity was approximately ($861.6) million as of September 30, 2025, also below the $50 million threshold.
• The company also failed the Minimum Share Price Criteria (Section 802.01C) as the average closing price of its ordinary shares fell below $1.00 per share over 30 consecutive trading days, with a 30-trading-day average closing price of $0.99 as of December 11, 2025.
• Trinseo intends to notify the NYSE within 10 days of its intention to regain compliance with the share price criteria within six months.
• The company plans to submit a plan to the NYSE within 45 days to address the market capitalization standard, aiming to regain compliance within 18 months.
• The notice does not have an immediate impact on the listing of the company's ordinary shares, which will continue to be traded on the NYSE during the cure periods, but the trading symbol will have a ".BC" designation.
• The non-compliance does not affect the company's ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements.

Sentiment

Score: 2

Explanation: The filing indicates severe financial distress and significant risk of delisting from the NYSE due to extremely low market capitalization, a substantial stockholders' deficit, and a sub-$1 share price. While the company outlines plans to regain compliance, the underlying financial metrics are very poor, suggesting a high level of negative sentiment and operational challenges.

Positives

• The notice has no immediate impact on the listing of the company's ordinary shares, which will continue to be listed and traded on the NYSE during the available cure periods.
• The current noncompliance does not affect the company's ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements.
• The company states it will continue to meet its customers' needs and supplier commitments.

Negatives

• The company's 30-trading-day average market capitalization was approximately $35.6 million, falling below the NYSE's $50 million minimum requirement.
• The company's last reported stockholders' deficit as of September 30, 2025, was approximately ($861.6) million, significantly below the NYSE's $50 million minimum stockholders' equity requirement.
• The company's 30-trading-day average closing share price was $0.99, falling below the NYSE's $1.00 per share minimum requirement.
• The company's trading symbol will have an added designation of ".BC" to indicate its status as below criteria with the NYSE continued listing standards.

Risks

• There is no assurance that the company will be able to comply with the continued listing standards of the NYSE, which could result in the delisting of its securities.
• Delisting could limit investors' ability to make transactions in the company's securities and subject shares to additional trading restrictions or requirements.
• Potential material adverse consequences of delisting include limited availability of market quotations, reduced liquidity and market price for ordinary shares, and application of Irish stamp duty to purchases.
• Delisting could lead to the determination that ordinary shares are a penny stock, requiring brokers to adhere to more stringent rules and possibly reducing trading activity.
• A negative impact on the company's reputation or business, impairment of its ability to award equity incentives to employees, limited analyst coverage, and a decreased ability to issue additional securities or obtain additional financing in the future are potential risks.
• Risks arising from the potential suspension of trading of the company's ordinary shares on the NYSE.
• Conditions in the global economy and capital markets, including persistent decreased customer demand and the impact of tariffs on global trade relations.
• Inability to successfully generate cost savings through restructuring and cost reduction initiatives.
• Inability to successfully execute business and transformation strategy.
• Increased costs or disruption in the supply of raw materials.
• Deterioration of the company's credit profile limiting access to commercial credit.
• Increased energy costs.
• Uncertainty regarding the timing of, and the company's ability to complete, a sale of its interest in Americas Styrenics.
• Compliance with laws and regulations impacting the business.
• Any disruptions in production at chemical manufacturing facilities, including those resulting from accidental spills or discharges.
• Current and future levels of indebtedness and the company's ability to service, repay or refinance its indebtedness.
• Inability to meet the covenants under existing indebtedness.
• Inability to generate cash flows from operations and achieve forecasted cash flows.

Future Outlook

The company intends to notify the NYSE within 10 days of its intention to regain compliance with the minimum share price criteria within six months. Additionally, it plans to submit a plan within 45 days to address the minimum market capitalization standard, aiming for compliance within 18 months. The company emphasizes its commitment to meeting customer needs and supplier commitments.

Management Comments

• "Trinseo will continue to meet its customers needs and supplier commitments."

Industry Context

The filing does not provide specific industry context beyond general risks related to the global economy, capital markets, decreased customer demand, and tariffs, which are common challenges for specialty material providers. The non-compliance issues are specific to the company's financial performance and market valuation rather than broader industry trends.

Stakeholder Impact

• Shareholders face potential risks including reduced liquidity, lower market price, application of Irish stamp duty, the possibility of shares being deemed a penny stock, and increased trading restrictions if delisted.
• Employees may be impacted by the impairment of the company's ability to award equity incentives.
• Customers and suppliers are assured that the company will continue to meet its needs and commitments, but the underlying financial distress could pose long-term operational risks.
• Creditors may face risks due to a deteriorating credit profile, which could limit the company's access to commercial credit and its ability to service or refinance existing indebtedness.

Next Steps

• Notify the NYSE within 10 days of intention to regain compliance with the Minimum Share Price Criteria within six months (Share Price Cure Period).
• Submit a plan to the NYSE within 45 days advising of definitive actions to regain compliance with the Minimum Market Capitalization Standard within 18 months (Market Cap Cure Period).
• If the NYSE accepts the plan, the company will be reviewed quarterly to confirm compliance.
• Regain compliance with the Minimum Share Price Criteria by achieving a closing share price of at least $1.00 and an average closing share price of at least $1.00 over a 30-trading-day period by the last trading day of any calendar month during the six-month cure period.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by a market capitalization significantly below NYSE requirements ($35.6M vs $50M minimum), a substantial stockholders' deficit of ($861.6M), and a sub-$1 share price. While the company has cure periods, the magnitude of the non-compliance, particularly the negative stockholders' equity, indicates fundamental business challenges and a high probability of eventual delisting. Delisting would severely impact liquidity, market price, and future financing capabilities, making the stock a high-risk investment with significant downside potential.

Keywords

NYSE, delisting, market capitalization, share price, non-compliance, Trinseo, TSE, 8-K, SEC filing, specialty materials, corporate governance, risk factors, listing standards